Clinical Trials Logo

Filter by:
NCT ID: NCT04034355 Terminated - Colorectal Cancer Clinical Trials

Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

POLAR-A
Start date: January 7, 2019
Phase: Phase 3
Study type: Interventional

This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal cancer (CRC).

NCT ID: NCT04033159 Terminated - Clinical trials for Centronuclear Myopathy

Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies

Unite-CNM
Start date: January 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)/preliminary efficacy of a new medicine called DYN101 in patients ≥ 16 years of age with CNM caused by mutations in Dynamin2 (DNM2) or Myotubularin1 (MTM1). The trial will consist of a consent, a screening period, a run-in period (if applicable), a Single dose treatment part (SAD) with 4 weeks of follow-up after the drug administration and a washout period of at least 12 weeks (followed by follow-up phone calls), a Multiple dose treatment part (MAD) of 12 weeks of weekly dosing, and a Multiple dose extension part of 12 weeks. All subjects will participate in the SAD, MAD, and MAD extension parts, unless they withdraw. During this time, multiple test will be performed in order to better understand how the drug is distributed and then later removed from the body and whether there any signs of an effect. As this trial is investigational, there is no defined, expected benefit for subjects who participate in this trial except a better knowledge of their disease.

NCT ID: NCT04032925 Terminated - Clinical trials for Myocardial Infarction

The Pressure-controlled Intermittent Coronary Sinus Occlusion on VentrIcular PERformance Study

PICSO-ViPER
Start date: August 3, 2021
Phase: Phase 2
Study type: Interventional

The PICSO ViPER study is a prospective single centre cohort study of the use of PICSO in patients presenting acute myocardial infarction and impaired function of the left ventricle and candidate to angioplasty the left anterior descending (LAD) coronary artery. The percutaneous coronary intervention (PCI) procedure will be undertaken in a standard fashion, in accordance with the Oxford University Hospitals NHS Trust (OUHT) departmental guidelines for PCI, and includes the use of pressure wire measurements before and after stent deployment. PICSO treatment will be added on top of the conventional treatment. The protocol will constitute of 5 main stages (that will all be performed during index angioplasty procedure). The protocol is complete at the end of the angioplasty procedure, and the patient will exit the study at this point. The five stages of the protocol are described below (for details see "Detailed Description"): - Baseline - PICSO treatment during pre-dilation - Stenting with PICSO support - Post-stent Physiology - PICSO treatment during post-dilation

NCT ID: NCT04032704 Terminated - Prostate Cancer Clinical Trials

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Start date: October 9, 2019
Phase: Phase 2
Study type: Interventional

This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

NCT ID: NCT04025632 Terminated - Clinical trials for Immune Mediated Necrotizing Myopathy

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Start date: November 7, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.

NCT ID: NCT04023981 Terminated - Pressure Ulcer Clinical Trials

Parafricta Bootees vs UK Standard Care to Prevent Heel Pressure Ulcers

Start date: October 26, 2017
Phase: N/A
Study type: Interventional

This randomised study will assess whether Parafricta bootees, when used in addition to normal standard care, can reduce the incidence of heel PUs in patients at very high risk of skin breakdown. The participant group will be hospital inpatients at high risk of PUs (Waterlow score of 20 or more) who are bedbound and do not have existing heel PUs. The participants will be randomised to an intervention arm using Parafricta plus standard care, or a control arm of standard care only. The primary outcome is incidence of heel PUs at day 3. Secondary outcomes are incidence of PUs at day 14, length of stay, severity of PUs, patient acceptability of device, cost-effectiveness.

NCT ID: NCT04023721 Terminated - Hepatitis B Clinical Trials

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Start date: June 18, 2019
Phase: Phase 2
Study type: Interventional

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.

NCT ID: NCT04021316 Terminated - Venous Ulcer Clinical Trials

Decellularised Dermis Allograft for the Treatment of Chronic Venous Leg Ulceration

DAVE
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Does the use of decellularised dermis allograft in addition to compression therapy promote healing in chronic venous leg ulceration compared to compression therapy alone

NCT ID: NCT04020679 Terminated - Chemotherapy Effect Clinical Trials

The Goals of Care Initiative

GOCI
Start date: June 11, 2019
Phase: N/A
Study type: Interventional

A single site hybrid implement-evaluation stepped wedge cluster randomised controlled trial in which cancer cluster groups (lung, colorectal, breast, renal, ovarian, upper GI & sarcoma) are randomised sequentially to initiate the Goals of Care Initiative into clinical practice.

NCT ID: NCT04009720 Terminated - Clinical trials for Aortic Valve Stenosis

RESPOND EDGE Post Market Study

RESPOND EDGE
Start date: October 11, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of the RESPOND EDGE post market study is to collect real world clinical and device performance outcomes data with the Lotus Edge™ Valve System used in routine clinical practice to demonstrate that the commercially available Lotus Edge Valve System is a safe and effective treatment for patients with severe calcific aortic stenosis.